ABEO Abeona Therapeutics Inc.

5.20
+0  (3%)
Previous Close 5.05
Open 5.05
Price To book 2.05
Market Cap 209.33M
Shares 40,255,000
Volume 242,590
Short Ratio 12.66
Av. Daily Volume 247,845

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17754557
  2. 8-K - Current report 17729197
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17726106
  4. 8-K - Current report 17630984
  5. 8-K - Current report 17622227

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment commenced September 2016.
ABO-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 updated data released February 17, 2017.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. Abeona to Present At Multiple Upcoming Conferences
  2. Edited Transcript of ABEO earnings conference call or presentation 10-Apr-17 2:00pm GMT
  3. ETFs with exposure to Abeona Therapeutics, Inc. : April 5, 2017
  4. Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
  5. Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 3, 2017
  6. Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
  7. Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
  8. Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
  9. Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
  10. Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
  11. In Honor of International Rare Disease Day, Abeona Therapeutics (Nasdaq: ABEO) Set to Ring the Nasdaq Stock Market Closing Bell
  12. Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
  13. Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
  14. Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
  15. 3 Companies Looking to Capitalize on Orphan Designation with Multiple Catalyst
  16. Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%
  17. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  18. ABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Abeona Therapeutics Inc. and a Lead Plaintiff Deadline of February 14, 2017
  19. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  20. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO) and Lead Plaintiff Deadline - February 14, 2017